Skip to main content
. 2020 Jun 8;28(7-8):396–405. doi: 10.1007/s12471-020-01439-5

Fig. 4.

Fig. 4

Schematic representation of hypothesis 2. ACE inhibitors (ACEIs) and angiotensin II type‑1 receptor blockers (ARBs) aggravate COVID-19 by upregulating ACE2, causing increased SARS-CoV‑2 entry and replication